Imatinib
- Generic Name
- Imatinib
- Brand Names
- Gleevec, Glivec, Imatinib Teva, Imatinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C29H31N7O
- CAS Number
- 152459-95-5
- Unique Ingredient Identifier
- BKJ8M8G5HI
- Background
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...
- Indication
Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
FDA Approves Danziten for Leukemia Subset That Does Not Require Fasting
The FDA approved Danziten, a nilotinib formulation without fasting requirements, for adults with newly diagnosed or resistant Philadelphia chromosome-positive chronic myeloid leukemia. Danziten aims to improve adherence by eliminating Tasigna's fasting restrictions, offering equivalent efficacy.
FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML
The FDA approved nilotinib (Danziten) for treating adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase and acute phase, who are resistant or intolerant to prior imatinib therapy. This is the first nilotinib approval without mealtime restrictions, offering a lower dose and improved bioavailability compared to standard nilotinib (Tasigna).
FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML
FDA approves nilotinib (Danziten) tablets without mealtime restrictions for treating Ph-positive CML, offering an alternative to Tasigna without fasting requirements. Danziten maintains Tasigna's efficacy with improved bioavailability, allowing lower doses and no meal restrictions, as supported by phase 3 ENESTnd and phase 1/2 Study A2101 trials.
Nilotinib Tablets Approved by FDA for Ph+ CML in Chronic Phase
FDA approves nilotinib tablets (Danziten) without mealtime restrictions for newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (CML) patients, including those in chronic or acute phase with resistance or intolerance to prior therapy. This new formulation eliminates fasting requirements and avoids cardiotoxicity concerns associated with the original nilotinib (Tasigna).
Precision Medicine Unfolds in Oncology, Bearing Substantial Implications for the Future
Precision cancer medicine's future lies in longitudinal monitoring via blood tests to detect early progression and actionable markers, enabling timely treatment adjustments and predicting efficacy. This approach aims to maintain patient quality of life while addressing cost concerns, leveraging advancements in molecular biology and somatic/germline mutations. The present sees expanded precision medicine roles, with standard-of-care treatments evolving based on molecular profiling. Future developments include routine molecular monitoring in blood, facilitating rapid therapy switches as cancer biology changes, transforming advanced cancer into a more chronic condition managed with targeted drugs.
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and ...
Scemblix (asciminib) granted FDA approval for newly diagnosed Ph+ CML-CP, showing superior efficacy, safety, and tolerability in ASC4FIRST Phase III trial vs. standard of care TKIs. Patients on Scemblix had fewer dose reductions and adverse reactions, addressing unmet needs in CML treatment.
Related Clinical Trials:
FDA Approves Scemblix for Some With Newly Diagnosed Chronic Myeloid Leukemia
FDA approved Scemblix for newly diagnosed chronic myeloid leukemia, based on ASC4FIRST trial showing 68% major molecular response rate at 48 weeks vs. 49% with tyrosine kinase inhibitors. Common side effects include rash, musculoskeletal pain, and upper respiratory tract infection.
Behind The Breakthroughs: Weaving Genomic Profiling Across Cancer Care
Luca Quagliata, PhD, discusses the journey of precision medicine, emphasizing the need for genomic profiling and decentralized clinical trials to enhance access and equity. He highlights the importance of collaboration with patients, pathologists, clinicians, payers, and pharma to realize the full potential of precision medicine globally.
Breakthroughs and Challenges in BCL-2 Inhibitor Therapy for CLL Treatment
BCL-2 inhibitors like venetoclax target BCL-2 protein to trigger apoptosis in cancer cells, overcoming challenges in drug design due to protein-protein interactions. Combination therapies with agents like BTK inhibitors or anti-CD20 antibodies enhance outcomes in CLL, offering tailored treatment options. Understanding individual tumor biology and patient profiles is crucial for effective therapy.
Asciminib Has Superior Response Rates in CML
Asciminib (Scemblix) shows promise in frontline CML treatment, with potential for treatment discontinuation. The ASC4FIRST trial demonstrated superior 48-week major molecular response rates compared to standard TKIs, and a favorable safety profile. Jorge Cortes, MD, discusses the implications for patient care and future research.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath